These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 8178077)

  • 1. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of hyperuricemia and gout].
    Pöllmann G; Kullich W; Klein G
    Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies in the long-term management of hyperuricaemia and gout.
    Stamp LK; O'Donnell JL; Chapman PT
    Intern Med J; 2007 Apr; 37(4):258-66. PubMed ID: 17388867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.
    Stuart RA; Gow PJ; Bellamy N; Campbell J; Grigor R
    N Z Med J; 1991 Mar; 104(908):115-7. PubMed ID: 2011292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Gröbner W
    Dtsch Med Wochenschr; 2002 Mar; 127(11):576. PubMed ID: 11894180
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperuricemia and gout.
    Sloan RW
    J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current treatment of hyperuricemia and gout].
    Vukotić D
    Med Pregl; 1982; 35(5-6):213-7. PubMed ID: 7177063
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
    Hilmi BA; Asmahan MI; Rosman A
    Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.